A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
Deep-vein thrombosis has a reported annual incidence of about 1.6 per 1000 in urban populations. 1 The incidence of first episodes of pulmonary embolism in acute care hospitals in the United States has been estimated to be 0.23 per 1000. 2 For both these problems, secondary prophylaxis with oral ant...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1995-06, Vol.332 (25), p.1661-1665 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1665 |
|---|---|
| container_issue | 25 |
| container_start_page | 1661 |
| container_title | The New England journal of medicine |
| container_volume | 332 |
| creator | Schulman, Sam Rhedin, Ann-Sofie Lindmarker, Per Carlsson, Anders Lärfars, Gerd Nicol, Peter Loogna, Enno Svensson, Else Ljungberg, Bengt Walter, Hans Viering, Stanka Nordlander, Sune Leijd, Barbro Jönsson, Kjell-Åke Hjorth, Martin Linder, Olle Boberg, Jonas |
| description | Deep-vein thrombosis has a reported annual incidence of about 1.6 per 1000 in urban populations.
1
The incidence of first episodes of pulmonary embolism in acute care hospitals in the United States has been estimated to be 0.23 per 1000.
2
For both these problems, secondary prophylaxis with oral anticoagulants is routinely given. This practice is based on a retrospective study by Coon et al.
3
and on subsequent randomized trials in which the incidence of recurrence was 26 to 29 percent over 12 weeks if the initial treatment with heparin was followed only by ineffective prophylaxis with heparin (as indicated by a . . . |
| doi_str_mv | 10.1056/NEJM199506223322501 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223983423</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1983912310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4181-f514dd3b8dc1f3dc7e7bc117b6eb9311bb9d16e4595633c2ab5f998f7651244c3</originalsourceid><addsrcrecordid>eNp9kctOwzAQRS0EEqXwBWwsYIcCnthO4mVVtTwEdMFrGTmOTVOSONipCn-PSxErwNLIsubcO9YdhA6BnAHhyfnd5PoWhOAkiWNK45gT2EID4JRGjJFkGw0IibOIpYLuoj3vFyQcYGKAViM8tk0nXeVti63B99U7ftb61eNV1c-_nre27ed-3Zw5WeNR21fKypdlLdseP8y1k90HlqbXDks8rZzv8aQLfqVea550a5c-cM42hdWh6so3-2jHyNrrg-97iB6nk4fxZXQzu7gaj24ixSCDyHBgZUmLrFRgaKlSnRYKIC0SXQgKUBSihEQzLnhCqYplwY0QmUkTDjFjig7R0ca3c_ZtqX2fL-zStWFkHqISGWUhsCE6_guCgAiIKZBA0Q2lnPXeaZN3rmqk-8iB5Os15L-sIahOvr2lV7I2Traq8j9SypMspesvnG6wpvF5qxfNv6afVVeSiw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983912310</pqid></control><display><type>article</type><title>A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Schulman, Sam ; Rhedin, Ann-Sofie ; Lindmarker, Per ; Carlsson, Anders ; Lärfars, Gerd ; Nicol, Peter ; Loogna, Enno ; Svensson, Else ; Ljungberg, Bengt ; Walter, Hans ; Viering, Stanka ; Nordlander, Sune ; Leijd, Barbro ; Jönsson, Kjell-Åke ; Hjorth, Martin ; Linder, Olle ; Boberg, Jonas</creator><creatorcontrib>Schulman, Sam ; Rhedin, Ann-Sofie ; Lindmarker, Per ; Carlsson, Anders ; Lärfars, Gerd ; Nicol, Peter ; Loogna, Enno ; Svensson, Else ; Ljungberg, Bengt ; Walter, Hans ; Viering, Stanka ; Nordlander, Sune ; Leijd, Barbro ; Jönsson, Kjell-Åke ; Hjorth, Martin ; Linder, Olle ; Boberg, Jonas ; the Duration of Anticoagulation Trial Study Group</creatorcontrib><description>Deep-vein thrombosis has a reported annual incidence of about 1.6 per 1000 in urban populations.
1
The incidence of first episodes of pulmonary embolism in acute care hospitals in the United States has been estimated to be 0.23 per 1000.
2
For both these problems, secondary prophylaxis with oral anticoagulants is routinely given. This practice is based on a retrospective study by Coon et al.
3
and on subsequent randomized trials in which the incidence of recurrence was 26 to 29 percent over 12 weeks if the initial treatment with heparin was followed only by ineffective prophylaxis with heparin (as indicated by a . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199506223322501</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Angiography ; Anticoagulants ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Compression therapy ; Defects ; Drug therapy ; Embolism ; Embolisms ; Health risk assessment ; Hemorrhage ; Medical disorders ; Medical imaging ; Medical research ; Medical sciences ; Perfusion ; Pharmacology. Drug treatments ; Protein C ; Protein deficiency ; Thromboembolism ; Thrombosis ; Veins & arteries ; Ventilators ; Warfarin</subject><ispartof>The New England journal of medicine, 1995-06, Vol.332 (25), p.1661-1665</ispartof><rights>Copyright © 1995 Massachusetts Medical Society. All rights reserved.</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4181-f514dd3b8dc1f3dc7e7bc117b6eb9311bb9d16e4595633c2ab5f998f7651244c3</citedby><cites>FETCH-LOGICAL-c4181-f514dd3b8dc1f3dc7e7bc117b6eb9311bb9d16e4595633c2ab5f998f7651244c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199506223322501$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199506223322501$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3568733$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Schulman, Sam</creatorcontrib><creatorcontrib>Rhedin, Ann-Sofie</creatorcontrib><creatorcontrib>Lindmarker, Per</creatorcontrib><creatorcontrib>Carlsson, Anders</creatorcontrib><creatorcontrib>Lärfars, Gerd</creatorcontrib><creatorcontrib>Nicol, Peter</creatorcontrib><creatorcontrib>Loogna, Enno</creatorcontrib><creatorcontrib>Svensson, Else</creatorcontrib><creatorcontrib>Ljungberg, Bengt</creatorcontrib><creatorcontrib>Walter, Hans</creatorcontrib><creatorcontrib>Viering, Stanka</creatorcontrib><creatorcontrib>Nordlander, Sune</creatorcontrib><creatorcontrib>Leijd, Barbro</creatorcontrib><creatorcontrib>Jönsson, Kjell-Åke</creatorcontrib><creatorcontrib>Hjorth, Martin</creatorcontrib><creatorcontrib>Linder, Olle</creatorcontrib><creatorcontrib>Boberg, Jonas</creatorcontrib><creatorcontrib>the Duration of Anticoagulation Trial Study Group</creatorcontrib><title>A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism</title><title>The New England journal of medicine</title><description>Deep-vein thrombosis has a reported annual incidence of about 1.6 per 1000 in urban populations.
1
The incidence of first episodes of pulmonary embolism in acute care hospitals in the United States has been estimated to be 0.23 per 1000.
2
For both these problems, secondary prophylaxis with oral anticoagulants is routinely given. This practice is based on a retrospective study by Coon et al.
3
and on subsequent randomized trials in which the incidence of recurrence was 26 to 29 percent over 12 weeks if the initial treatment with heparin was followed only by ineffective prophylaxis with heparin (as indicated by a . . .</description><subject>Angiography</subject><subject>Anticoagulants</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Compression therapy</subject><subject>Defects</subject><subject>Drug therapy</subject><subject>Embolism</subject><subject>Embolisms</subject><subject>Health risk assessment</subject><subject>Hemorrhage</subject><subject>Medical disorders</subject><subject>Medical imaging</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Perfusion</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein C</subject><subject>Protein deficiency</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Veins & arteries</subject><subject>Ventilators</subject><subject>Warfarin</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kctOwzAQRS0EEqXwBWwsYIcCnthO4mVVtTwEdMFrGTmOTVOSONipCn-PSxErwNLIsubcO9YdhA6BnAHhyfnd5PoWhOAkiWNK45gT2EID4JRGjJFkGw0IibOIpYLuoj3vFyQcYGKAViM8tk0nXeVti63B99U7ftb61eNV1c-_nre27ed-3Zw5WeNR21fKypdlLdseP8y1k90HlqbXDks8rZzv8aQLfqVea550a5c-cM42hdWh6so3-2jHyNrrg-97iB6nk4fxZXQzu7gaj24ixSCDyHBgZUmLrFRgaKlSnRYKIC0SXQgKUBSihEQzLnhCqYplwY0QmUkTDjFjig7R0ca3c_ZtqX2fL-zStWFkHqISGWUhsCE6_guCgAiIKZBA0Q2lnPXeaZN3rmqk-8iB5Os15L-sIahOvr2lV7I2Traq8j9SypMspesvnG6wpvF5qxfNv6afVVeSiw</recordid><startdate>19950622</startdate><enddate>19950622</enddate><creator>Schulman, Sam</creator><creator>Rhedin, Ann-Sofie</creator><creator>Lindmarker, Per</creator><creator>Carlsson, Anders</creator><creator>Lärfars, Gerd</creator><creator>Nicol, Peter</creator><creator>Loogna, Enno</creator><creator>Svensson, Else</creator><creator>Ljungberg, Bengt</creator><creator>Walter, Hans</creator><creator>Viering, Stanka</creator><creator>Nordlander, Sune</creator><creator>Leijd, Barbro</creator><creator>Jönsson, Kjell-Åke</creator><creator>Hjorth, Martin</creator><creator>Linder, Olle</creator><creator>Boberg, Jonas</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19950622</creationdate><title>A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism</title><author>Schulman, Sam ; Rhedin, Ann-Sofie ; Lindmarker, Per ; Carlsson, Anders ; Lärfars, Gerd ; Nicol, Peter ; Loogna, Enno ; Svensson, Else ; Ljungberg, Bengt ; Walter, Hans ; Viering, Stanka ; Nordlander, Sune ; Leijd, Barbro ; Jönsson, Kjell-Åke ; Hjorth, Martin ; Linder, Olle ; Boberg, Jonas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4181-f514dd3b8dc1f3dc7e7bc117b6eb9311bb9d16e4595633c2ab5f998f7651244c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Angiography</topic><topic>Anticoagulants</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Compression therapy</topic><topic>Defects</topic><topic>Drug therapy</topic><topic>Embolism</topic><topic>Embolisms</topic><topic>Health risk assessment</topic><topic>Hemorrhage</topic><topic>Medical disorders</topic><topic>Medical imaging</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Perfusion</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein C</topic><topic>Protein deficiency</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Veins & arteries</topic><topic>Ventilators</topic><topic>Warfarin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schulman, Sam</creatorcontrib><creatorcontrib>Rhedin, Ann-Sofie</creatorcontrib><creatorcontrib>Lindmarker, Per</creatorcontrib><creatorcontrib>Carlsson, Anders</creatorcontrib><creatorcontrib>Lärfars, Gerd</creatorcontrib><creatorcontrib>Nicol, Peter</creatorcontrib><creatorcontrib>Loogna, Enno</creatorcontrib><creatorcontrib>Svensson, Else</creatorcontrib><creatorcontrib>Ljungberg, Bengt</creatorcontrib><creatorcontrib>Walter, Hans</creatorcontrib><creatorcontrib>Viering, Stanka</creatorcontrib><creatorcontrib>Nordlander, Sune</creatorcontrib><creatorcontrib>Leijd, Barbro</creatorcontrib><creatorcontrib>Jönsson, Kjell-Åke</creatorcontrib><creatorcontrib>Hjorth, Martin</creatorcontrib><creatorcontrib>Linder, Olle</creatorcontrib><creatorcontrib>Boberg, Jonas</creatorcontrib><creatorcontrib>the Duration of Anticoagulation Trial Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schulman, Sam</au><au>Rhedin, Ann-Sofie</au><au>Lindmarker, Per</au><au>Carlsson, Anders</au><au>Lärfars, Gerd</au><au>Nicol, Peter</au><au>Loogna, Enno</au><au>Svensson, Else</au><au>Ljungberg, Bengt</au><au>Walter, Hans</au><au>Viering, Stanka</au><au>Nordlander, Sune</au><au>Leijd, Barbro</au><au>Jönsson, Kjell-Åke</au><au>Hjorth, Martin</au><au>Linder, Olle</au><au>Boberg, Jonas</au><aucorp>the Duration of Anticoagulation Trial Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism</atitle><jtitle>The New England journal of medicine</jtitle><date>1995-06-22</date><risdate>1995</risdate><volume>332</volume><issue>25</issue><spage>1661</spage><epage>1665</epage><pages>1661-1665</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Deep-vein thrombosis has a reported annual incidence of about 1.6 per 1000 in urban populations.
1
The incidence of first episodes of pulmonary embolism in acute care hospitals in the United States has been estimated to be 0.23 per 1000.
2
For both these problems, secondary prophylaxis with oral anticoagulants is routinely given. This practice is based on a retrospective study by Coon et al.
3
and on subsequent randomized trials in which the incidence of recurrence was 26 to 29 percent over 12 weeks if the initial treatment with heparin was followed only by ineffective prophylaxis with heparin (as indicated by a . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJM199506223322501</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1995-06, Vol.332 (25), p.1661-1665 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223983423 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Angiography Anticoagulants Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Compression therapy Defects Drug therapy Embolism Embolisms Health risk assessment Hemorrhage Medical disorders Medical imaging Medical research Medical sciences Perfusion Pharmacology. Drug treatments Protein C Protein deficiency Thromboembolism Thrombosis Veins & arteries Ventilators Warfarin |
| title | A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T20%3A05%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Comparison%20of%20Six%20Weeks%20with%20Six%20Months%20of%20Oral%20Anticoagulant%20Therapy%20after%20a%20First%20Episode%20of%20Venous%20Thromboembolism&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Schulman,%20Sam&rft.aucorp=the%20Duration%20of%20Anticoagulation%20Trial%20Study%20Group&rft.date=1995-06-22&rft.volume=332&rft.issue=25&rft.spage=1661&rft.epage=1665&rft.pages=1661-1665&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199506223322501&rft_dat=%3Cproquest_cross%3E1983912310%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983912310&rft_id=info:pmid/&rfr_iscdi=true |